Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab Plus CIK Therapy for Advanced Melanoma
NCT02498756Phase 2Not yet recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Aug 2015
- Primary completion
- Aug 2038
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
A Phase 2 trial of unmodified CIK in melanoma, sponsored by Changzhou First People's Hospital. Planned start Aug 2015; status: not yet recruiting.
02
Drugs
unmodified CIK
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02498756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02498756.